A new pathway supporting innovative approaches to the safe, timely, and efficient development of medicines to improve patient access was updated on 23rd August 2021.
The Innovative Licensing and Access Pathway (ILAP) intends to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications, and repurposed medicines.
The ILAP is open to both commercial and non-commercial developers of medicines (UK-based and or global). It comprises of an Innovation Passport designation, a Target Development Profile (TDP) and provides applicants with access to a toolkit to support all stages of the design, development, and approvals process.
The permanent partners in the ILAP are:
The Medicines and Healthcare products Regulatory Agency (MHRA)
National Institute for Health and Care Excellence (NICE)
Scottish Medicines Consortium (SMC)
Supporting partners include:
NHS England and NHS Improvement
Health Research Authority (HRA)
National Institute for Health Research (NIHR)
Check out More details on ILAP here.
Comentarios